<i>In vivo</i>disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters

Selvi Durmuş(The Netherlands Cancer Institute), Alfred H. Schinkel(Oncode Institute), Olaf van Tellingen(Dutch Cancer Society), Jyoti Naik(Amsterdam UMC Location University of Amsterdam), Els Wagenaar(The Netherlands Cancer Institute), Levi C.M. Buil(Cancer Genomics Centre)
International Journal of Cancer
February 20, 2014
10.1002/ijc.28797
Cited by 53

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
|PubMed|2002|688